| Literature DB >> 32082397 |
Qing Zhou1, Wei-Xin Zhang1, Zong-Qi He2, Ben-Sheng Wu2, Zhao-Feng Shen1, Hong-Tao Shang1, Tuo Chen1, Qiong Wang1, Yu-Gen Chen1, Shu-Tang Han1.
Abstract
BACKGROUND: Dehydrocostus lactone (DL), one of the main active constituents in Aucklandia lappa Decne. (Muxiang), reported to have anti-inflammatory, antiulcer, and immunomodulatory properties. However, the effect of DL on ulcerative colitis (UC) has not been reported. To analyze the anti-inflammatory potential role of DL in UC, we provide a mechanism for the pharmacological action of DL.Entities:
Year: 2020 PMID: 32082397 PMCID: PMC7011397 DOI: 10.1155/2020/5659738
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The chemical structures of dehydrocostus lactone.
Colon histological lesion score.
| Score | Criterion |
|---|---|
| 0 | Normal tissue |
| 1 | Superficial epithelial damage |
| 2 | Focal ulcer confined to the mucosa |
| 3 | Focal transmural infammation and ulceration |
| 4 | Extensive transmural ulcer and infammation, normal mucosa between lesions |
| 5 | Extensive flaky transmural ulcers and infammation |
Primers and amplification conditions used for RT-PCR in BALB/c mice.
| Primers | Primer sequences | |
|---|---|---|
| Sense | Antisense | |
| iNOS | 5′-CCCTTCCGAAGTTTCTGGCAGCA-3′ | 5′-GGCTGTCAGAGCCTCGTGGCTTT-3′ |
| COX2 | 5′-CACTACATCCTGACCCACTT-3′ | 5′-ATGCTCCTGCTTGAGTATGT-3′ |
| IL-6 | 5′-GGCGGATCGGATGTTGTGAT-3′ | 5′-GGACCCCAGACAATCGGTTG-3′ |
| GP130 | 5′-CCGTGTGGTTACATCTACCCT-3′ | 5′-CGTGGTTCTGTTGATGACAGTG-3′ |
| STAT3 | 5′-CAATACCATTGACCTGCCGAT-3′ | 5′-GAGCGACTCAAACTGCCCT-3′ |
| IL-17 | 5′-TGAAAACACAGAAGTAACGTCC-3′ | 5′-CCCAGGAGGAAATTGTAATGGG-3′ |
| IL-23 | 5′-ATGCTGGATTGCAGAGCAGTA-3′ | 5′-ACGGGGCACATTATTTTTAGTCT-3′ |
| MUC2 | 5′-TCCAGGTCTCGACATTAGCAG-3′ | 5′-GTGCTGAGAGTTTGCGTGTCT-3′ |
| XBP1s | 5′-GTGGACCAGTTAAGCATGAGG-3′ | 5′-GCTCTCGGCGCTTGTTGAT-3′ |
|
| 5′-GAATCCGAGAGGATAAGGACCA-3′ | 5′-TCCATTGAAAGGGCAATAGGGA-3′ |
Figure 2Protective role of DL against DSS-induced colitis in mice. (a) Body weight changes after DSS-induced colitis. (b) Disease activity index (DAI). Animal model of chronic DSS-induced UC in BALB/c mice. P < 0.05 and P < 0.01, when compared to the model group.
Histological assessment.
| Group | Number ( | Pathology score |
|---|---|---|
| Normal | 10 | 0 |
| Model | 10 | 4.33 ± 0.52 |
| Mes | 10 | 0.62 ± 0.55 |
| DL-L | 10 | 1.66 ± 0.82 |
| DL-M | 10 | 1.06 ± 0.40 |
| DL-H | 10 | 0.75 ± 0.32 |
P < 0.05 and P < 0.01, when compared to the normal group; P < 0.05 and P < 0.01, when compared to the model group.
Figure 3DL reduced inflammatory cytokines expression. (a) TNF-α. (b) IL-1β. (c) MCP-1. (d) MPO. (e) SOD. (f) IL-6. (g) IL-17. (h) IL-23. Data are presented as the mean ± SD. P < 0.05 and P < 0.01, when compared to the normal group; P < 0.05 and P < 0.01, when compared to the model group (n = 10).
Figure 4DL downregulated IL-6/STAT3 inflammatory signaling pathway. (a) iNOS. (b) COX2. (c) IL-6. (d) GP130. (e) STAT3. (f) IL-17. (g) IL-23. P < 0.05 and P < 0.01, when compared to the normal group; P < 0.05 and P < 0.01, when compared to the model group (n = 10).
Figure 5DL maintained colorectal mucosal barrier-related regulatory factors. (a) MUC2. (b) XBP1s. (c) α-defensin. P < 0.05 and P < 0.01, when compared to the normal group; P < 0.05 and P < 0.01, when compared to the model group (n = 10).